Report : South and Central America Next-generation Antibody Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Therapeutic Area (Oncology, and Autoimmune or Inflammatory) and Technology (Antibody-drug conjugates, Bispecific antibodies, Fc engineered antibodies, Antibody fragments & antibody-like proteins, and Biosimilar antibody products)

The oncology segment by therapeutic area is estimated to lead the market growth during the forecast period.

According to a new market research study of “South and Central America Next-generation Antibody Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Therapeutic Area, Technology and Country.” The South and Central America (SCAM) next-generation antibody market are expected to reach US$ 695.60 million by 2028 from US$ 333.92 million in 2021. It is estimated to grow at a CAGR of 1% from 2021 to 2028. The report highlights trends prevailing in the South and Central America next-generation antibody market and the factors driving market along with those that act as hindrances.

Continuous medical science improvements and research & developments extend longevity and improve quality of life. Next-generation antibodies are majorly designed to treat various types of cancer. At the same time, new candidates are also being explored for other indications such as infectious diseases and central nervous system disorders. According to Genentech's Senior Vice President of Research Biology, next-generation antibodies have the potential to treat every condition. In addition, the Catalent Biologics Vice President and General Manager believe that the new modalities being incorporated into next-generation antibodies not only offer improved performance over their monoclonal counterparts but also help in offering the potential for new mechanisms of action, allowing access to multiple targets and multiple targeting within the same molecule.

Market players are innovating and advancing their technology to develop new products and therapies using next-generation antibodies and conjugates. For instance, in October 2021, Merck, a leading science and technology company, announced the launch of new technology and expanded the capacity of its Life Science business to produce advanced next-generation Antibody-Drug Conjugate (ADC) therapies. These initiatives underscore Merck's continued investment in novel modalities and support its efforts to double its ADC and high-potent active pharmaceutical ingredient (HPAPI) capacity in the near future. Additionally, in clinical trials, antibody therapies are increasingly being studied and approved, with over 570 therapies in various clinical stages, including 62 in late-stage clinical trials. Therefore, the developments mentioned above would result in significant trends in the next-generation antibody market during the forecast period.

South and Central America witnessed a massive number of COVID-19 cases. The increasing number of cases in Brazil, Peru, Chile, Ecuador, and Venezuela is expected to impact the market over the forecast period negatively.

A considerable number of countries in South America have very underdeveloped healthcare infrastructure. For instance, Peru has less than 1000 intensive care unit beds for its 32 million inhabitants. Furthermore, supply chain disruption caused due to congestion of ports and disturbances in other transport means had a substantial impact on the distribution of associated devices in the region. These factors are currently aiding the SCAM next-generation antibody market and are projected to continue supporting it over the forecast period.

Based on therapeutic area, the South and Central America next-generation antibody market has been segmented into oncology and autoimmune or inflammatory. Based on application, the South and Central America market is segmented into antibody-drug conjugates, bispecific antibodies, Fc engineered antibodies, antibody fragments and antibody-like proteins, and biosimilar antibody products. Geographically, the South and Central America next-generation antibody market is sub-segmented into Brazil, Argentina and Rest of South and Central America.

F. HOFFMANN-LA ROCHE LTD., Takeda Pharmaceutical Company Limited, Pfizer Inc., Catalent Inc and AstraZeneca are among the leading companies operating in the South and Central America next-generation antibody market.

Contact Us
Contact Person: Sameer Joshi 
Phone: +1-646-491-9876
Email Id:

Download Free PDF Brochure